Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tarik Wasfie

Trauma Surgery Flint, MI Medical Doctor

NPI 1225029739 CMS profile 711744

1127 Villa Linde Ct Suite 41, Flint, MI 48532

Open in the dashboard

General payments

$3,746

66 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,000 paid to institutions, not to them · program year 2019

Through program year 2025, Tarik Wasfie of Flint, MI is reported in the CMS Open Payments database as having received $3,746 across 66 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,000 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 63rd percentile of Trauma Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $677 9
2024 General $778 9
2023 General $852 13
2022 General $543 11
2021 General $330 9
2020 General $182 3
2019 General $384 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tarik Wasfie
  • Trauma Surgery median
  • Middle half of Trauma Surgery
  • National median

In program year 2025, general payments to Tarik Wasfie were reported at $677. Among 762 Trauma Surgery profiles paid that year, the median was $280 and the middle half received between $87 and $1,585.

Show as a table
Year Tarik Wasfie Trauma Surgery median Middle half National median
2019 $384 $153 $56–$644 $163
2020 $182 $123 $39–$342 $114
2021 $330 $142 $45–$556 $132
2022 $543 $172 $59–$732 $149
2023 $852 $213 $83–$1,200 $160
2024 $778 $237 $86–$1,280 $164
2025 $677 $280 $87–$1,585 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $494 13 payments
  2. TELA Bio, Inc. $329 3 payments
  3. Innovation Technologies Inc $265 2 payments
  4. Ethicon US, LLC $265 3 payments
  5. Acera Surgical, Inc. $246 2 payments
  6. Zimmer Biomet Holdings, Inc. $229 2 payments
  7. Solventum Corporation $227 4 payments
  8. KLS-Martin L.P. $202 11 payments
  9. KCI USA, Inc $188 2 payments
  10. Medtronic, Inc. $143 5 payments
  11. Other $1,159 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,746 66 payments
Products named General payments · program years 2019–2025
  1. VISTASEAL $269 3 payments
  2. Irrisept $265 2 payments
  3. PREVENA $247 4 payments
  4. Restrata Wound Matrix $246 2 payments
  5. SURGICEL NU-KNIT $212 2 payments
  6. V.A.C. VERAFLO $169 3 payments
  7. ABTHERA $147 3 payments
  8. AdvantageRib $146 1 payment
  9. OviTex 2S $139 1 payment
  10. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $135 1 payment
  11. Other $3,799 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

159

Median for General Surgery: 59

Drug cost

$1,896

Median for General Surgery: $393

Branded share of claims

37.1%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ibuprofen Generic 34 $438
Fenofibrate Fenofibrate Nanocrystallized Brand 13 $334
Enalapril Maleate Generic 11 $331
Levothyroxine Sodium Generic 20 $234
Atorvastatin Calcium Generic 12 $232
Silver Sulfadiazine Generic 12 $207
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 20 $52
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 26 $41
Azithromycin Generic 11 $28

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$36,049

Medicare's payments for the services billed

Medicare patients

115

Average age 74

Services billed

284

71 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Ischemic heart disease 44%
Chronic kidney disease 43%
Diabetes 39%
COPD 38%
Heart failure 37%
Atrial fibrillation 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

66 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Trauma Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record